Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity.
Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W. Zhong W, et al. Among authors: gimotty pa. Cell Rep. 2023 Oct 31;42(10):113224. doi: 10.1016/j.celrep.2023.113224. Epub 2023 Oct 8. Cell Rep. 2023. PMID: 37805922 Free PMC article.
Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: gimotty pa. Ann Oncol. 2023 Sep;34(9):806-812. doi: 10.1016/j.annonc.2023.06.006. Epub 2023 Jul 4. Ann Oncol. 2023. PMID: 37414215 Clinical Trial.
PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma.
Sharma G, Ojha R, Noguera-Ortega E, Rebecca VW, Attanasio J, Liu S, Piao S, Lee JJ, Nicastri MC, Harper SL, Ronghe A, Jain V, Winkler JD, Speicher DW, Mastio J, Gimotty PA, Xu X, Wherry EJ, Gabrilovich DI, Amaravadi RK. Sharma G, et al. Among authors: gimotty pa. JCI Insight. 2022 Oct 24;7(20):e165688. doi: 10.1172/jci.insight.165688. JCI Insight. 2022. PMID: 36278493 Free PMC article. No abstract available.
Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC. Sharon CE, et al. Among authors: gimotty pa. Ann Oncol. 2024 Apr 13:S0923-7534(24)00076-0. doi: 10.1016/j.annonc.2024.03.002. Online ahead of print. Ann Oncol. 2024. PMID: 38614876 No abstract available.
Author Correction: Stiff matrix induces exosome secretion to promote tumour growth.
Wu B, Liu DA, Guan L, Myint PK, Chin L, Dang H, Xu Y, Ren J, Li T, Yu Z, Jabban S, Mills GB, Nukpezah J, Chen YH, Furth EE, Gimotty PA, Wells RG, Weaver VM, Radhakrishnan R, Wang XW, Guo W. Wu B, et al. Among authors: gimotty pa. Nat Cell Biol. 2024 Mar;26(3):490-491. doi: 10.1038/s41556-024-01375-1. Nat Cell Biol. 2024. PMID: 38347184 No abstract available.
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Sung AD, Koll T, Gier SH, Racioppi A, White G, Lew M, Free M, Agarwal P, Bohannon LM, Johnson EJ, Selvan B, Babushok DV, Frey NV, Gill SI, Hexner EO, Martin M, Perl AE, Pratz KW, Luger SM, Chao NJ, Fisher AL, Stadtmauer EA, Porter DL, Loren AW, Bhatt VR, Gimotty PA, McCurdy SR. Sung AD, et al. Among authors: gimotty pa. Transplant Cell Ther. 2024 Apr;30(4):415.e1-415.e16. doi: 10.1016/j.jtct.2024.01.062. Epub 2024 Jan 17. Transplant Cell Ther. 2024. PMID: 38242440
189 results